CB-86

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

CB-86
Identifiers
  • N-cyclopropyl-8-[3-hydroxy-5-(2-methyloctan-2-yl)phenoxy]octanamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC26H43NO3
Molar mass417.634 g·mol−1
3D model (JSmol)
  • CCCCCCC(C)(C)C1=CC(=CC(=C1)OCCCCCCCC(=O)NC2CC2)O
  • InChI=1S/C26H43NO3/c1-4-5-6-11-16-26(2,3)21-18-23(28)20-24(19-21)30-17-12-9-7-8-10-13-25(29)27-22-14-15-22/h18-20,22,28H,4-17H2,1-3H3,(H,27,29)
  • Key:PVAOGZXUOOHSMN-UHFFFAOYSA-N

CB-86 is a synthetic cannabinoid drug which was developed as a hybrid between classical/nonclassical cannabinoids such as THC and CP 47,497 with endogenous cannabinoid ligands such as anandamide. It acts as a partial agonist at CB1 receptors with a Ki of 5.6 nM, and an antagonist of CB2 receptors with a Ki of 7.9 nM. It has analgesic effects in studies on mice.[1]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).